Vizgen

VizgenVizgen
Vizgen

Vizgen

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

DR 512019Active166Waltham, United States
Rate

About

Vizgen is a leader in spatial biology and multiomics innovation, providing technologies that enable researchers to uncover deep insights into human biology and disease. Their platforms, such as MERSCOPE and MERFISH, allow for high-resolution spatial transcriptomics and proteomics, mapping RNA and protein in tissues to reveal cell states, interactions, and disease mechanisms.
Frequently asked

What does Vizgen do?

Vizgen is a leader in spatial biology and multiomics innovation, providing technologies that enable researchers to uncover deep insights into human biology and disease. Their platforms, such as MERSCOPE and MERFISH, allow for high-resolution spatial transcriptomics and proteomics, mapping RNA and protein in tissues to reveal cell states, interactions, and disease mechanisms.

What is Vizgen's revenue?

StartupHub estimates Vizgen's annual revenue at $21.0M (range $11.2M to $60.1M, 68% confidence), based on comparable companies in the sector.

What is Vizgen's valuation?

StartupHub estimates Vizgen's effective valuation at $718.7M (range $423.8M to $1.0B, 22% confidence), based on comparable companies in the sector.

How much funding has Vizgen raised?

Vizgen has raised a total of $170M in funding. The most recent round on record is Series E.

Where is Vizgen headquartered?

Vizgen is headquartered in Waltham, United States.

When was Vizgen founded?

Vizgen was founded in 2019.

What industry does Vizgen operate in?

Vizgen operates in Biotechnology, Life Sciences, Spatial Biology, Genomics, Proteomics, Multiomics.

How many employees does Vizgen have?

Vizgen has approximately 166 people on record.

Does Vizgen have an affiliate program?

Yes, Vizgen has an affiliate program. The program runs on Self-hosted affiliate. Register here: https://www.vizgen.com/affiliates

HEADCOUNT
166
DOMAIN RATING
51
Comments

No comments yet. Be the first to share your take.